ArticlePharmaceutics2019
Cabazitaxel-Loaded Nanocarriers for Cancer Therapy with Reduced Side Effects.
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 56 citations in OpenAlex.
- The Potential Protective Effects of Resveratrol Against Cabazitaxel-Induced Oxidative Stress and Cardiotoxicity in Rats.Cardiovascular toxicology · 2026Article
- Nanosystems for delivery of indolicidin peptide.Frontiers in medical technology · 2026Review
- Enhanced Efficacy and Safety: Cabazitaxel Nanodispersions as a Novel Therapeutic Platform against Prostate Cancer.AAPS PharmSciTech · 2025Article
- Inhalable Nano Formulation of Cabazitaxel: A Comparative Study with Intravenous Route.Macromolecular bioscience · 2025Article
- Enhanced therapeutics of cabazitaxel via polycarboxylate conjugation: improved solubility, safety, and antitumor efficacy.Frontiers in immunology · 2025Article
- Topical Drug Delivery of Concentrated Cabazitaxel in an α-Tocopherol and DMSO Solution.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery.Marine drugs · 2022Article
- Nanomedicines for Overcoming Cancer Drug Resistance.Pharmaceutics · 2022Review
- Imidazole-Based pH-Sensitive Convertible Liposomes for Anticancer Drug Delivery.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Stealth Liposomal Chemotherapeutic Agent for Triple Negative Breast Cancer with Improved Pharmacokinetics.Nanotheranostics · 2022Article
- Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models.International journal of pharmaceutics · 2021Article
- Therapeutic potential of thymoquinone in combination therapy against cancer and cancer stem cells.World journal of clinical oncology · 2021Review
- Role of Exosomes for Delivery of Chemotherapeutic Drugs.Critical reviews in therapeutic drug carrier systems · 2021Review
- Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer.European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 2021Article
- Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy.Acta biomaterialia · 2020Article
- The Wnt non-canonical signaling modulates cabazitaxel sensitivity in prostate cancer cells.PloS one · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jevtana
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.